Complementary asymmetric routes to (R)-2-(7-hydroxy-2,3-dihydro-1 H-pyrrolo[1,2-a]indol-1-yl)acetate

Organic Letters

Volumn 14, Issue 24, 2012, Pages 6306-6309

  Schrader, Thomas O ^a   Johnson, Benjamin R ^a,b   Lopez, Luis ^a   Kasem, Michelle ^a   Gharbaoui, Tawfik ^a,c   Sengupta, Dipanjan ^a,c   Buzard, Daniel ^a   Basmadjian, Christine ^a,d   Jones, Robert M ^a  

^a ARENA PHARMACEUTICALS   (United States)

^b Takeda San Diego Inc   (United States)

^c DART NEUROSCIENCE LLC   (United States)

^d UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

(R) 2 (7 HYDROXY 2,3 DIHYDRO 1H PYRROLO(1,2 A)INDOL 1 YL)ACETATE; (R)-2-(7-HYDROXY-2,3-DIHYDRO-1H-PYRROLO(1,2-A)INDOL-1-YL)ACETATE; ACETIC ACID DERIVATIVE; DRUG DERIVATIVE; FINGOLIMOD; INDOLE DERIVATIVE; PROPANEDIOL DERIVATIVE; PYRROLE DERIVATIVE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ARTICLE; CATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG POTENTIATION; STEREOISOMERISM; SYNTHESIS;

ACETATES; CATALYSIS; INDOLES; MOLECULAR STRUCTURE; PROPYLENE GLYCOLS; PYRROLES; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; STEREOISOMERISM;

EID: 84871589941     PISSN: 15237060     EISSN: 15237052     Source Type: Journal    
DOI: 10.1021/ol303070k     Document Type: Article

References (28)

1. Mutoh, T.; Rivera, R.; Chun, J. Br. J. Pharmacol. 2012, 165, 829-844
2. Kiuchi, M.; Adachi, K.; Kohara, T.; Minoguchi, M.; Hanano, T.; Aoki, Y.; Mishina, T.; Arita, M.; Nakao, N.; Ohtsuki, M.; Hoshino, Y.; Teshima, K.; Chiba, K.; Sasaki, S.; Fujita, T. J. Med. Chem. 2000, 43, 2946-2961
3. http://www.gilenya.com/info/multiple-sclerosis/multiple-sclerosis- information.jsp.
4. Gonzalez-Cabrera, P. J.; Cahalan, S. M.; Ferguson, J.; Rosen, H. Curr. Immunol. Rev. 2012, 8, 170-180
5. Chiba, K.; Adachi, K. Future Med. Chem. 2012, 4, 771-781
6. Matsuura, M.; Imayoshi, T.; Chiba, K.; Okumoto, T. Inflamm. Res. 2000, 49, 404-410
7. Kitabayashi, H.; Isobe, M.; Watanabe, N.; Suzuki, J.; Yazaki, Y.; Sekiguchi, M. J. Cardiovasc. Pharmacol. 2000, 35, 410-416
8. Daniel, C.; Sartory, N.; Zahn, N.; Geisslinger, G.; Radeke, H.; Stein, J. J. Immunol. 2007, 178, 2458-2468
9. Bolli, M. H.; Lescop, C.; Nayler, O. Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 2011, 11, 726-757
10. Buzard, D. J.; Thatte, J.; Lerner, M.; Edwards, J.; Jones, R. M. Expert Opin. Ther. Pat. 2008, 18, 1141-1159
11. Buzard, D. J.; Han, S.; Lopez, L.; Kawasaki, A.; Moody, J.; Thoresen, L.; Ullman, B.; Lehmann, J.; Calderon, I.; Zhu, X.; Gharbaoui, T.; Sengupta, D.; Krishnan, A.; Gao, Y.; Edwards, J.; Barden, J.; Morgan, M.; Usmani, K.; Chen, C.; Sadeque, A.; Thatte, J.; Solomon, M.; Fu, L.; Whelan, K.; Liu, L.; Al-Shamma, H.; Gatlin, J.; Le, M.; Xing, C.; Espinola, S.; Jones, R. M. Bioorg. Med. Chem. Lett. 2012, 22, 4404-4409
12. Jones, R. M.; Buzard, D. J.; Kawasaki, A. M.; Kim, S.; Thoresen, L.; Lehmann, J.; Zhu, X. WO 2010027431, 2010.
13. Smith, A. B., III; Visnick, M. Tetrahedron Lett. 1985, 26, 3757-3760
14. Smith, A. B., III; Visnick, M.; Haseltine, J. N.; Sprengeler, P. A. Tetrahedron 1986, 42, 2957-2969
15. Smith, A. B., III; Davulcu, A. H.; Cho, Y. S.; Ohmoto, K.; Kürti, L.; Ishiyama, H. J. Org. Chem. 2007, 72, 4596-4610
16. Clark, R. D.; Muchowski, J. M.; Fisher, L. E.; Flippin, L. A.; Repke, D. B.; Souchet, M. Synthesis 1991, 10, 871-878
17. Peters, R.; Waldmeier, P.; Joncour, A. Org. Process Res. Dev. 2005, 9, 508-512
18. Evans, D. A.; Wu, L. D.; Wiener, J. J. M.; Johnson, J. S.; Ripin, D. H. B.; Tedrow, J. S. J. Org. Chem. 1999, 64, 6411-6417
19. Hepperle, M. E.; Campbell, D. A.; Winn, D. T.; Betancort, J. M. WO 2009102876, 2009.
20. Another significant feature of N -acyl oxazolidinone 5 is that epimerization at the α-stereogenic carbon in these systems is strongly discouraged, suggesting that the R -stereochemistry at the asymmetric carbon atom would remain unaffected by the strongly basic conditions encountered during the dilithiation reaction. See: Evans, D. A. Aldrichimica Acta 1982, 15, 23-32
21. Bis(ester) 11 was prepared in two steps from N -acyl oxazolidinone 5 by peroxolysis followed by methylation. For removal of the chiral auxiliary by lithium hydroxide/hydrogen peroxide, see: Evans, D. A.; Britton, T. C.; Ellman, J. A. Tetrahedron Lett. 1987, 28, 6141-6144
22. Subsequent to this work, the iridium-Walphos-catalyzed enantioselective hydrogenation of a related tricyclic enoate was reported. See: Tudge, M.; Savarin, C. G.; DiFelice, K.; Maligres, P.; Humphrey, G.; Reamer, B.; Tellers, D. M.; Hughes, D. Org. Process Res. Dev. 2010, 14, 787-798
23. Tang, W.; Zhang, X. Chem. Rev. 2003, 103, 3029-3069
24. Woodmansee, D. H.; Pfaltz, A. Chem. Commun. 2011, 47, 7912-7916
25. Minnaard, A. J.; Feringa, B. L.; Lefort, L.; de Vries, J. G. Acc. Chem. Res. 2007, 40, 1267-1277
26. Lipshutz, B. H.; Servesko, J. M.; Taft, B. R. J. Am. Chem. Soc. 2004, 126, 8352-8353
27. Deng, J.; Hu, X.-P.; Huang, J.-D.; Yu, S.-B.; Wang, D.-Y.; Duan, Z.-C.; Zheng, Z. J. Am. Chem. Soc. 2008, 73, 6022-6024
28. Deutsch, C.; Krause, N.; Lipshutz, B. H. Chem. Rev. 2008, 108, 2916-2927